Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates on its global Phase 3 program for hepatitis C (HCV) and to outline early progress in a new hepatitis E (HEV) antiviral program. CEO and founder J.P. Sommadossi was joined in

The World Health Organisation (WHO) has released its 2023 Essential Diagnostics List, which includes key updates to aid in the global management of various health conditions. Notably, the list now incorporates essential tests for hepatitis E virus (HEV) and personal glucose monitoring devices for diabetes, aiming to improve outbreak management and enhance disease control.

Dr. Reddy’s launches Hevaxin, India’s first DCGI-approved vaccine, to combat the deadly waterborne Hepatitis E virus.

Dr. Reddy’s Laboratories has introduced Hevaxin, a reco […]

Dr. Reddy’s Laboratories announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India.  Hevaxin is the only vaccine approved by […]

Dr. Reddy’s Laboratories has announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India, marking a significant expansion of the company’s preventive healthcare portfolio.​ Hevaxin is currently the only vaccine approved by the Drug Controller General of India (DCGI) for active immunisation against HEV infection […]

Dr. Reddy’s Laboratories has launched Hevaxin, a novel vaccine for preventing Hepatitis E in India, targeting adults aged 18-65. This vaccine promises long-lasting immunity and supports the National Viral Hepatitis Control Programme.

The company said Hevaxin is the only hepatitis E vaccine approved by the Drug Controller General of India (DCGI) and is indicated for active immunisation against HEV infection

Dr. Reddy’s launches Hevaxin, India’s first approved vaccine for preventing Hepatitis E virus infection in adults aged 18 to 65.

Atea Pharmaceuticals Inc. (AVIR) is advancing late-stage antiviral programs, led by its Phase 3 hepatitis C trials of Bemnifosbuvir and Ruzasvir. With enrollment completed in the pivotal C-BEYOND study and topline results expected in 2026, the company is positioning itself to deliver shorter, more tolerable treatment options.

Hepatitis E virus (HEV) infection is a frequent cause of acute viral hepatitis. Immunocompromised patients, especially those under anti-CD20 regimens, are prone to chronic or treatment-resistant cour…

Every year there are an estimated 20 million hepatitis E infections, over 3 million symptomatic cases of hepatitis E, and 56 600 hepatitis E-related deaths.

The United Kingdom hepatitis E diagnostic tests market is set to witness steady growth over the next decade driven by rising awareness of viral hepatitis improved disease surveillance and increasing testing across hospital and public health laboratories According to a …

In an era where viral infections continue to challenge global health, groundbreaking research has shed light on the durability of natural immunity against hepatitis E virus (HEV) reinfection. A recent study published in Nature Communications by Liu et al. delves into the

Nature Communications – Hepatitis E virus is a leading cause of acute viral hepatitis and antibodies can persist for years post-infection. Here, the authors quantify the protective effects of…

The demand for Hepatitis E diagnostic tests in the United States is gradually increasing as awareness of viral hepatitis expands and diagnostic capabilities improve across healthcare systems Hepatitis E virus HEV though historically associated with developing regions is now increasingly …

Hepatitis E virus (HEV) is probably the most common cause of acute hepatitis in humans worldwide (1). HEV is a single-stranded, positive-sense RNA virus with a genome size of approximately 7.2 kb (2). Human HEV belongs to the genus Paslahepevirus, subfamily Orthohepevirinae, and the family Hepeviridae. The members of species Paslahepevirus balayani have been classified […]

Scientists at the University Medical Center Hamburg-Eppendorf (UKE) have examined pig slurry from the northwestern region of Germany and detected

BackgroundViral hepatitis remains a major public health challenge in China, contributing significantly to global disease burden. Understanding spatiotemporal…

Demand for Hepatitis E Diagnostic Tests in UK is expected to reach USD 6.2 million and likely to surge at a CAGR of 5.0% during forecast period from 2026 to 2036.